AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24961493 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 2110
Study 22746950 — intervention group
Group type: EXPERIMENTAL
Intervention: Factorial morphspaces
Number of subjects: 0
Study 22746950 — intervention group
Group type: COMPARATOR
Intervention: Blended morphspaces
Number of subjects: 0
Study 21041812 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid meal
Number of subjects: 10
Study 17485161 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG 27 mg
Number of subjects: 430
Study 17485161 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG 13.5 mg
Number of subjects: 430
Study 17485161 — intervention group
Group type: COMPARATOR
Intervention: MMC 30 mg
Number of subjects: 430
Study 15517239 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak Systolic Velocity (PSV) cutpoint of 200 cm/s for increased TCD surveillance
Number of subjects: 1937
Study 15517239 — intervention group
Group type: EXPERIMENTAL
Intervention: PSV cutpoint of 250 cm/s for consideration of chronic transfusion treatment
Number of subjects: 1937
Study 15517239 — intervention group
Group type: COMPARATOR
Intervention: TAMM velocity
Number of subjects: 1937
Study 15517239 — intervention group
Group type: COMPARATOR
Intervention: End Diastolic Velocity (EDV)
Number of subjects: 1937
Study 12092017 — intervention group
Group type: EXPERIMENTAL
Intervention: Hands-on method
Number of subjects: 1161
Study 12092017 — intervention group
Group type: COMPARATOR
Intervention: Hands-poised method
Number of subjects: 1161
Study 9454524 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 2078
Study 9454524 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfonylurea
Number of subjects: 2078
Study 9454524 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 2078
Study 9454524 — intervention group
Group type: COMPARATOR
Intervention: Diet-controlled group
Number of subjects: 2078
Study 9454524 — intervention group
Group type: COMPARATOR
Intervention: Primary diet failure group
Number of subjects: 2078
Study 9454524 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultralente insulin
Number of subjects: 2078
Study 7614164 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical podophyllum resin 25% solution
Number of subjects: 10
Study 7614164 — intervention group
Group type: COMPARATOR
Intervention: Control side (untreated)
Number of subjects: 10
Study 1535495 — intervention group
Group type: EXPERIMENTAL
Intervention: Balneotherapy
Number of subjects: 158
Study 1535495 — intervention group
Group type: EXPERIMENTAL
Intervention: Underwater traction bath
Number of subjects: 158
Study 1535495 — intervention group
Group type: EXPERIMENTAL
Intervention: Underwater massage
Number of subjects: 158
Study 1535495 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 158
Study 6571946 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate-dose methotrexate plus intrathecal methotrexate
Number of subjects: 506
Study 6571946 — intervention group
Group type: COMPARATOR
Intervention: Cranial irradiation plus intrathecal methotrexate
Number of subjects: 506
Study 31655891 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D Phase‐Sensitive Inversion Recovery (PSIR)
Number of subjects: 54
Study 31655891 — intervention group
Group type: COMPARATOR
Intervention: Conventional dataset (3D Short Tau Inversion Recovery (STIR) and T2‐weighted imaging)
Number of subjects: 54
Study 29728889 — intervention group
Group type: EXPERIMENTAL
Intervention: Flapless technique
Number of subjects: 20
Study 29728889 — intervention group
Group type: COMPARATOR
Intervention: Flap technique
Number of subjects: 20
Study 25286894 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior exhaustive training (PE)
Number of subjects: 27
Study 25286894 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional training (TR)
Number of subjects: 27
Study 25286894 — intervention group
Group type: COMPARATOR
Intervention: Untrained control (CO)
Number of subjects: 27
Study 24970601 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-guided exposure (T+)
Number of subjects: 42
Study 24970601 — intervention group
Group type: COMPARATOR
Intervention: Self-guided exposure (T-)
Number of subjects: 42
Study 22369224 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatments for alcohol-dependent women
Number of subjects: 181
Study 19172031 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical finasteride (1% gel)
Number of subjects: 45
Study 19172031 — intervention group
Group type: COMPARATOR
Intervention: Oral finasteride (1 mg tablet)
Number of subjects: 45
Study 19172031 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (topical and oral finasteride)
Number of subjects: 45
Study 17426085 — intervention group
Group type: EXPERIMENTAL
Intervention: Diane(35) Diario (35 microg of ethinyl‐estradiol plus 2 mg of cyproterone acetate)
Number of subjects: 34
Study 17426085 — intervention group
Group type: COMPARATOR
Intervention: Metformin (850 mg twice daily)
Number of subjects: 34
Study 17426085 — intervention group
Group type: EXPERIMENTAL
Intervention: Diane(35) Diario
Number of subjects: 34
Study 17426085 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 34
Study 17426085 — intervention group
Group type: COMPARATOR
Intervention: Diane(35) Diario and Metformin
Number of subjects: 34
Study 16322169 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral and nutrition intervention (BEH)
Number of subjects: 10
Study 16322169 — intervention group
Group type: COMPARATOR
Intervention: Usual care control condition (CTL)
Number of subjects: 10
Study 12006162 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo (60 mg TID)
Number of subjects: 26
Study 12006162 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 12006162 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 26
Study 10220205 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg Q10 daily for 3 months
Number of subjects: 34
Study 10220205 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 7637151 — intervention group
Group type: EXPERIMENTAL
Intervention: 25g glucose infusion in an hour (glucose group)
Number of subjects: 74
Study 7637151 — intervention group
Group type: COMPARATOR
Intervention: No glucose infusion (control group)
Number of subjects: 74
Study 2617243 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold cardioplegic solution allowed to pass through the lungs (n = 27)
Number of subjects: 55
Study 2617243 — intervention group
Group type: COMPARATOR
Intervention: Cold cardioplegic solution evacuated via right atrium (n = 28)
Number of subjects: 55
Study 1086714 — intervention group
Group type: EXPERIMENTAL
Intervention: methotrexate-citrovorum factor rescue plus cyclophosphamide
Number of subjects: 35
Study 1086714 — intervention group
Group type: COMPARATOR
Intervention: methotrexate-citrovorum factor rescue alone
Number of subjects: 35
Study 31464945 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation sedation with acclimatization visit
Number of subjects: 0
Study 31464945 — intervention group
Group type: COMPARATOR
Intervention: Inhalation sedation without acclimatization visit
Number of subjects: 0
Study 28159196 — intervention group
Group type: EXPERIMENTAL
Intervention: Droxidopa
Number of subjects: 0
Study 26057627 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (48 weeks treatment with 1.5 μg/kg Pegylated Interferon alpha and 800-1400 mg Ribavirin)
Number of subjects: 99
Study 26057627 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (36 weeks treatment with 1.5 μg/kg Pegylated Interferon alpha and 800-1400 mg Ribavirin)
Number of subjects: 99
Study 26057627 — intervention group
Group type: COMPARATOR
Intervention: Historical control group (SVR 70%)
Number of subjects: 99
Study 23076431 — intervention group
Group type: EXPERIMENTAL
Intervention: N(G)‐nitro‐l‐arginine methyl ester hydrochloride (L‐NAME, 20 mM)
Number of subjects: 17
Study 23076431 — intervention group
Group type: EXPERIMENTAL
Intervention: Eutectic mixture of local anaesthetics (EMLA) cream (2.5% lidocaine and 2.5% prilocaine)
Number of subjects: 17
Study 21568191 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention (8-week group intervention, weekly 2-hour sessions)
Number of subjects: 21
Study 21568191 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 21
Study 19781410 — intervention group
Group type: EXPERIMENTAL
Intervention: EPC capturing stent
Number of subjects: 2560
Study 19781410 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stent
Number of subjects: 2560
Study 19781410 — intervention group
Group type: COMPARATOR
Intervention: Drug-eluting stent (DES)
Number of subjects: 2560
Study 17070146 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ivabradine (5 mg twice daily for 2 weeks then target dose of 7.5 mg twice daily)
Number of subjects: 9650
Study 17070146 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9650
Study 15799170 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20mg/day
Number of subjects: 50
Study 15799170 — intervention group
Group type: COMPARATOR
Intervention: Routine group (placebo)
Number of subjects: 50
Study 11774942 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone survey
Number of subjects: 100
Study 11774942 — intervention group
Group type: COMPARATOR
Intervention: E-mail survey
Number of subjects: 100
Study 11774942 — intervention group
Group type: COMPARATOR
Intervention: Standard mail survey
Number of subjects: 100
Study 11774942 — intervention group
Group type: COMPARATOR
Intervention: Nonresponders (contacted by telephone)
Number of subjects: 100
Study 11774942 — intervention group
Group type: COMPARATOR
Intervention: All groups (telephone, e-mail, standard mail)
Number of subjects: 100
Study 9245674 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention including a UVR reduction curriculum and home-based activities for children and parents.
Number of subjects: 169
Study 9245674 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no specific intervention details provided).
Number of subjects: 169
Study 8343267 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 121
Study 8343267 — intervention group
Group type: COMPARATOR
Intervention: Latamoxef
Number of subjects: 121
Study 3525829 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress self-help package administered by general practitioners
Number of subjects: 0
Study 3525829 — intervention group
Group type: COMPARATOR
Intervention: Existing general practitioner treatment without the package
Number of subjects: 0
Study 31543407 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast adaptation (10 hours wear from the first day)
Number of subjects: 74
Study 31543407 — intervention group
Group type: COMPARATOR
Intervention: Gradual adaptation (4 hours on the first day, increasing by 2 hours daily until reaching 10 hours)
Number of subjects: 74
Study 31543407 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast adaptation silicone-hydrogel
Number of subjects: 74
Study 31543407 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast adaptation hydrogel
Number of subjects: 74
Study 28921624 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (180 mg loading dose, then 90 mg twice daily)
Number of subjects: 60
Study 28921624 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 60
Study 28921624 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 60
Study 27267068 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow-derived mononuclear cells (BM-MNC) treatment (early, administered 5 to 7 days after AMI)
Number of subjects: 200
Study 27267068 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow-derived mononuclear cells (BM-MNC) treatment (late, administered 3 to 4 weeks after AMI)
Number of subjects: 200
Study 27267068 — intervention group
Group type: COMPARATOR
Intervention: Control group (open-labeled)
Number of subjects: 200
Study 27267068 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (combined clinical end point)
Number of subjects: 200
Study 27267068 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (1-year mortality)
Number of subjects: 200
Study 23583566 — intervention group
Group type: EXPERIMENTAL
Intervention: FBC 9/320 μg bid
Number of subjects: 66
Study 23583566 — intervention group
Group type: COMPARATOR
Intervention: SFC 50/250 μg bid
Number of subjects: 66
Study 23577078 — intervention group
Group type: EXPERIMENTAL
Intervention: Brown beans evening meal
Number of subjects: 16
Study 23577078 — intervention group
Group type: COMPARATOR
Intervention: White wheat bread (WWB) evening meal
Number of subjects: 16
Study 20390820 — intervention group
Group type: EXPERIMENTAL
Intervention: Coaching group (in vivo feedback)
Number of subjects: 60
Study 20390820 — intervention group
Group type: COMPARATOR
Intervention: No coaching group (control)
Number of subjects: 60
Study 18547996 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoiesis stimulating agents (epoetin) treatment in anemic patients (23 patients)
Number of subjects: 100
Study 18547996 — intervention group
Group type: EXPERIMENTAL
Intervention: Anemic patients (50 patients)
Number of subjects: 100
Study 18547996 — intervention group
Group type: COMPARATOR
Intervention: Non-anemic patients (50 patients)
Number of subjects: 100
Study 15641007 — intervention group
Group type: EXPERIMENTAL
Intervention: ICEX TSB socket
Number of subjects: 26
Study 15641007 — intervention group
Group type: COMPARATOR
Intervention: Conventional PTB socket
Number of subjects: 26
Study 12815694 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylaspartate (NAA) levels in MS patients
Number of subjects: 11
Study 12815694 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (Cr) levels in MS patients
Number of subjects: 11
Study 12815694 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline (Cho) levels in MS patients
Number of subjects: 11
Study 12815694 — intervention group
Group type: COMPARATOR
Intervention: Choline (Cho) levels in controls
Number of subjects: 11
Study 12815694 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall metabolite levels comparison
Number of subjects: 11
Study 10589367 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination cyclosporine and chloroquine
Number of subjects: 0
Study 10589367 — intervention group
Group type: COMPARATOR
Intervention: Antimalarials
Number of subjects: 0
Study 8724305 — intervention group
Group type: EXPERIMENTAL
Intervention: Visible electromagnetic fields (light condition; mean 4750 lux, SD 2337 lux)
Number of subjects: 14
Study 8724305 — intervention group
Group type: COMPARATOR
Intervention: Nonvisible electromagnetic fields (no light condition)
Number of subjects: 14
Study 8724305 — intervention group
Group type: EXPERIMENTAL
Intervention: Visible electromagnetic fields (light condition)
Number of subjects: 14
Study 1884543 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent adjuvant chemotherapy
Number of subjects: 74
Study 1884543 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-agent, alternating, adjuvant postoperative chemotherapy
Number of subjects: 74
Study 1884543 — intervention group
Group type: EXPERIMENTAL
Intervention: Limb-salvage operations
Number of subjects: 74
Study 1884543 — intervention group
Group type: COMPARATOR
Intervention: Amputation
Number of subjects: 74
Study 1884543 — intervention group
Group type: COMPARATOR
Intervention: Limb-salvage operations vs Amputation
Number of subjects: 74
Study 1884543 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating, multiagent, adjuvant chemotherapy
Number of subjects: 74
Study 6614524 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% bupivacaine
Number of subjects: 54
Study 6614524 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% chloroprocaine
Number of subjects: 54
Study 6614524 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine
Number of subjects: 54
Study 6614524 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 1:200,000 epinephrine
Number of subjects: 54
Study 31331699 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg per day for up to 1 year
Number of subjects: 72
Study 31331699 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate-vinblastine (vinblastine 5 mg/m2 per dose and methotrexate 30 mg/m2 per dose, administered weekly for 6 months and then every other week for 6 months)
Number of subjects: 72
Study 31331699 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib
Number of subjects: 72
Study 31331699 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate-vinblastine
Number of subjects: 72
Study 29282088 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy alone (4 cycles of FLOT chemotherapy)
Number of subjects: 271
Study 29282088 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy followed by surgical resection of primary and metastases
Number of subjects: 271
Study 29282088 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with trastuzumab if Her2+ (4 cycles)
Number of subjects: 271
Study 25301758 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C plus BCG
Number of subjects: 407
Study 25301758 — intervention group
Group type: COMPARATOR
Intervention: BCG alone
Number of subjects: 407
Study 25092377 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (up to 300 mg/d)
Number of subjects: 30
Study 25092377 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 30
Study 25092377 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 22745533 — intervention group
Group type: EXPERIMENTAL
Intervention: COPE-active intervention (standardized physiotherapeutic reactivation intervention)
Number of subjects: 51
Study 22745533 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 51
Study 19181719 — intervention group
Group type: COMPARATOR
Intervention: Speed-of-processing training
Number of subjects: 2014
Study 19181719 — intervention group
Group type: EXPERIMENTAL
Intervention: No-contact control
Number of subjects: 2014
Study 18654123 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MINT)
Number of subjects: 190
Study 18654123 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 190
Study 16340383 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg/day valproate
Number of subjects: 49
Study 16340383 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg/day topiramate
Number of subjects: 49
Study 11904609 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg misoprostol at 6‐hour intervals
Number of subjects: 150
Study 11904609 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microg misoprostol at 6‐hour intervals
Number of subjects: 150
Study 11904609 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 microg misoprostol followed by 200 microg at 6‐hour intervals
Number of subjects: 150
Study 10447786 — intervention group
Group type: EXPERIMENTAL
Intervention: One-legged exercise training
Number of subjects: 16
Study 10447786 — intervention group
Group type: COMPARATOR
Intervention: Two-legged exercise training
Number of subjects: 16
Study 10447786 — intervention group
Group type: EXPERIMENTAL
Intervention: Both training regimens
Number of subjects: 16
Study 10447786 — intervention group
Group type: EXPERIMENTAL
Intervention: One-legged training
Number of subjects: 16
Study 7818151 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body warming and cooling
Number of subjects: 56
Study 7818151 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body rewarming
Number of subjects: 56
Study 7818151 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body cooling
Number of subjects: 56
Study 2256579 — intervention group
Group type: EXPERIMENTAL
Intervention: High Group I allergenic house dust (8.4 micrograms/g)
Number of subjects: 19
Study 2256579 — intervention group
Group type: COMPARATOR
Intervention: Low Group I allergenic house dust (0.66 micrograms/g)
Number of subjects: 19
Study 2256579 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural exposure to house dust
Number of subjects: 19
Study 254678 — intervention group
Group type: EXPERIMENTAL
Intervention: Family centered nursing approach
Number of subjects: 30
Study 254678 — intervention group
Group type: EXPERIMENTAL
Intervention: Staff nurse‐patient relationship prior to transfer
Number of subjects: 30
Study 254678 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 31906999 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilastine 20 mg
Number of subjects: 150
Study 31906999 — intervention group
Group type: COMPARATOR
Intervention: Increased H1-antihistamine dose (twofold)
Number of subjects: 150
Study 30265341 — intervention group
Group type: EXPERIMENTAL
Intervention: E-cigs with 10% of labeled propylene glycol (PG), glycerol (G), and nicotine
Number of subjects: 25
Study 30265341 — intervention group
Group type: COMPARATOR
Intervention: Smokers smoking 10 non-filter cigarettes spiked with labeled PG, G, and nicotine
Number of subjects: 25
Study 28350412 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured sexual rehabilitation programme (30-min individualized session)
Number of subjects: 68
Study 28350412 — intervention group
Group type: COMPARATOR
Intervention: Written information alone
Number of subjects: 68
Study 26515383 — intervention group
Group type: COMPARATOR
Intervention: High Intensity (HI) exercise
Number of subjects: 277
Study 26515383 — intervention group
Group type: COMPARATOR
Intervention: Low-to-Moderate Intensity (LMI) exercise
Number of subjects: 277
Study 23398595 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal treatment plus radiotherapy
Number of subjects: 875
Study 23398595 — intervention group
Group type: COMPARATOR
Intervention: Hormonal treatment alone
Number of subjects: 875
Study 21281668 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitness
Number of subjects: 170
Study 21281668 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatness
Number of subjects: 170
Study 21281668 — intervention group
Group type: EXPERIMENTAL
Intervention: Executive function, mathematics and reading achievement, and parent ratings of child behavior
Number of subjects: 170
Study 21281668 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher ratings
Number of subjects: 170
Study 19103990 — intervention group
Group type: EXPERIMENTAL
Intervention: Crush stenting
Number of subjects: 350
Study 19103990 — intervention group
Group type: COMPARATOR
Intervention: Provisional side-branch T-stenting
Number of subjects: 350